JP Morgan Chase
AMLX icon

JP Morgan Chase’s Amylyx Pharmaceuticals AMLX Stock Holding History

JP Morgan Chase’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.04M Buy
159,663
+93,116
+140% +$1.31M ﹤0.01% 4084
2025
Q4 		$804K Buy
66,547
+30,703
+86% +$417K ﹤0.01% 4743
2025
Q3 		$487K Sell
35,844
-52,145
-59% -$491K ﹤0.01% 5053
2025
Q2 		$564K Buy
87,989
+33,920
+63% +$165K ﹤0.01% 4715
2025
Q1 		$191K Sell
54,069
-1,537
-3% -$5.47K ﹤0.01% 5261
2024
Q4 		$210K Sell
55,606
-84,953
-60% -$400K ﹤0.01% 5453
2024
Q3 		$455K Buy
140,559
+83,048
+144% +$187K ﹤0.01% 4956
2024
Q2 		$109K Sell
57,511
-352,248
-86% -$683K ﹤0.01% 5469
2024
Q1 		$1.16M Buy
409,759
+337,871
+470% +$4.42M ﹤0.01% 4234
2023
Q4 		$1.06M Sell
71,888
-19,077
-21% -$292K ﹤0.01% 4293
2023
Q3 		$1.67M Sell
90,965
-99,331
-52% -$2.1M ﹤0.01% 3687
2023
Q2 		$4.1M Buy
190,296
+88,596
+87% +$2.39M ﹤0.01% 3029
2023
Q1 		$2.98M Buy
101,700
+51,999
+105% +$1.81M ﹤0.01% 3238
2022
Q4 		$1.84M Buy
49,701
+30,437
+158% +$1.08M ﹤0.01% 3628
2022
Q3 		$542K Buy
19,264
+13,132
+214% +$328K ﹤0.01% 4406
2022
Q2 		$118K Buy
6,132
+1,635
+36% +$19.4K ﹤0.01% 5335
2022
Q1 		$58K Buy
+4,497
New +$102K ﹤0.01% 5734

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

JP Morgan Chase's AMLX Position: Q1 2026 in Review

JP Morgan Chase increased its Amylyx Pharmaceuticals (AMLX) stake by 140% in Q1 2026, buying an estimated $1.31M and bringing the position to 159,663 shares worth $2.04M. The position accounts for ﹤0.01% of the portfolio, ranked #4084.

JP Morgan Chase first reported a position in AMLX in Q1 2022 and has held it in 17 quarters since. The position peaked at $4.1M in Q2 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • JP Morgan Chase held 159,663 shares of Amylyx Pharmaceuticals worth $2.04M as of Q1 2026.
  • JP Morgan Chase bought 93,116 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $1.31M.
  • Amylyx Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4084 holding.
  • JP Morgan Chase first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • JP Morgan Chase's Amylyx Pharmaceuticals position peaked at $4.1M in Q2 2023.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.